Your browser doesn't support javascript.
loading
Dupilumab-associated ocular manifestations: A review of clinical presentations and management.
Wu, Duoduo; Daniel, Benjamin S; Lai, Andre J X; Wong, Nathan; Lim, Dawn K A; Murrell, Dedee F; Lim, Blanche X H; Mehta, Jodhbir S; Lim, Chris H L.
Afiliação
  • Wu D; Yong Loo Lin School of Medicine, National University of Singapore.
  • Daniel BS; St George Hospital, Kogarah, Sydney, NSW, Australia; St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Lai AJX; Yong Loo Lin School of Medicine, National University of Singapore.
  • Wong N; Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
  • Lim DKA; Yong Loo Lin School of Medicine, National University of Singapore; Department of Ophthalmology, National University Health System, Singapore.
  • Murrell DF; St George Hospital, Kogarah, Sydney, NSW, Australia; School of Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Lim BXH; Yong Loo Lin School of Medicine, National University of Singapore; Department of Ophthalmology, National University Health System, Singapore.
  • Mehta JS; Duke-NUS Graduate Medical School, Singapore; Singapore Eye Research Institute, Singapore; Singapore National Eye Centre, Singapore.
  • Lim CHL; Yong Loo Lin School of Medicine, National University of Singapore; Department of Ophthalmology, National University Health System, Singapore; Singapore Eye Research Institute, Singapore; School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia. Electronic address
Surv Ophthalmol ; 67(5): 1419-1442, 2022.
Article em En | MEDLINE | ID: mdl-35181280
Dupilumab is a first-in-class biologic approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of multiple atopic diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Since gaining traction as an effective treatment modality, multiple reports have highlighted the many ocular side effects associated with dupilumab usage. These range from mild diseases, such as conjunctivitis, dry eyes, and blepharitis, to more severe manifestations such as intraocular inflammation and cicatrizing conjunctivitis. The pathogenesis behind these manifestations remains controversial, but are likely multi-factorial. We review the current evidence surrounding ocular manifestations of dupilumab-associated disease and proposed treatments to provide an overview of this unique disease entity. With increasing usage of dupilumab, formal recommendations regarding the treatment of dupilumab-associated ocular disease are warranted to provide standardized clinical guidance. Furthermore, it is important for health care practitioners to remain abreast with existing literature to counsel and empower patients with the knowledge surrounding contemporary treatments for atopic diseases and their associated sideeffects.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Conjuntivite / Dermatite Atópica Tipo de estudo: Diagnostic_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Conjuntivite / Dermatite Atópica Tipo de estudo: Diagnostic_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article